A senior investment executive with more than two decades of financial leadership and legal experience, Cary Meadow guides the Los Angeles-based investment company Grade 6 Oil, LLC. As the name suggests, the company maintains holdings in upstream and midstream production and is one of the region's most active pursuers of oil production assets. Additionally, Cary Meadow serves as executive chairman of Patriot Environmental Services, which he acquired in 2014. He has raised more than $100 million for the company, which primarily serves railroads, pipeline operators, oil and gas producers, and utilities. Before his current endeavors, Cary Meadow served six years as chairman and CEO of Channel Investment Advisors, where he managed private equity investments in companies like Sunny Frog Oil and Pavement Recycling Systems, as well partnered with two New York-based private equity firms. Earlier in his career, he held executive roles with K1 Ventures, Pacific Capital Group, Telemundo Network, and Miramax Films. He began his career as an associate attorney with Hill Wynne Troop & Meisinger. Mr. Meadow earned his juris doctor from the University of Southern California Law Center and holds a bachelor's degree in finance from the University of Texas. In addition to his professional pursuits, he is a member of the board of governors as well as the investment and pension committees for Cedars Sinai Medical Center.
Don't wanna be here? Send us removal request.
Statistics
We looked inside some of the posts by carymeadow-blog and here's what we found interesting.
Average Info
Notes Per Post
1
Likes Per Post
1
Reblog Per Post
0
Reply Per Post
0
Number of Posts By Type
Text
1
Last Seen Tumblr Blogs
Fun Fact
There were a total of 171.5 billion posts on Tumblr in 2019.
Text
New Treatment May Prevent Blindness for Those with Rare Eye Disease
Experience in the environmental and energy sectors, executive Cary Meadow leads multiple organizations including Patriot Environmental, Grade 6 Oil, LLC, and Sunny Frog Oil. Cary Meadow is also passionate about charity work and serves on the board of numerous leading organizations, including on the governing board and investment and pension committees at Cedars-Sinai Medical Center. In a recent trial conducted by the surgical department at Cedars-Sinai Medical Center and other medical centers nationwide, a new treatment for a rare eye disease showed promise in symptom improvement and quality of life. The results of the study were recently published in The New England Journal of Medicine. The eye disease in question was thyroid eye disease, a rare autoimmune disease that can affect vision. It causes inflammation in the muscles and fatty tissue behind the eyes, often leading to bulging of the eyes and causing double vision, light sensitivity, and sometimes even blindness. Eighty-three percent of patients that were administered the drug teprotumumab showed a measurable reduction in the bulging of the eyes caused by the disease. The new drug, now on the market as Tepezza, is the first drug approved for this condition, and it presents a non-invasive, non-surgical alternative to treatment that is quite effective.
1 note
·
View note